Clinical Trial Update: rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study [Phase 3]

View source ↗

Summary

Phase 3 pharmacokinetic study of rFVIII-Fc produced by AryoGen Pharmed Co. for severe hemophilia A has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFVIII-Fc (recombinant factor VIII Fc fusion protein)

Snippet

Sponsor: AryoGen Pharmed Co. | Conditions: Severe Hemophilia A | Phase 3 | Status: COMPLETED